Wednesday, January 05, 2005

Lilly and Novartis schizophrenia drugs may increase diabetes risk - Pharmaceutical Business Review

"Researchers have found that patients treated with the anti-psychotic agents clozapine and olanzapine, marketed as Novartis's Clozaril and Eli Lilly's Zyprexa respectively, may be at an increased risk for insulin resistance, a major risk factor for diabetes.":

// posted by Unknown @ 9:37 p.m.
Comments: Post a Comment

Subscribe to Post Comments [Atom]





<< Home

This page is powered by Blogger. Isn't yours?

Subscribe to Posts [Atom]